

Human Recombinant Muscarinic Acetylcholine Receptor M2 Stable Cell Line Cat. No. M00258 Version 05292014

I	Introduction	1
II	Background	1
Ш	Representative Data	2
IV	Thawing and Subculturing	3
V	References	4
	Limited Use License Agreement	5

I. INTRODUCTION

Catalog Number: M00258
Cell Line: CHO-K1/M2/Gα15
Gene Synonyms: CHRM2

Expressed Gene: GenBank Accession Number NM_000739; no expressed tags

Host Cell: CHO-K1/Gα15

Quantity: Two vials of frozen cells (3×10⁶ per vial)

Stability: 16 passages

Applications: Functional assays for M2 receptor

Freeze Medium: 45% culture medium, 45% FBS, and 10% DMSO

Complete Growth Medium: Ham's F12, 10% FBS

Culture Media: Ham's F12, 10% FBS, 200 µg/ml Zeocin, 100 µg/ml Hygromycin B

Mycoplasma Status: Negative

Storage: Liquid nitrogen immediately upon delivery

II. BACKGROUND

Muscarinic acetylcholine receptors belong to a superfamily of seven-TM-domain receptors that interact with G-proteins to initiate intracellular responses. Five muscarinic receptor subtypes have been identified and named from M1 to M5. The M2 muscarinic receptor couples to $G_{i/o}$ to inhibit cAMP production. GenScript co-transfected human M2 with $G\alpha15$ in the CHO-K1 which supports high levels of recombinant M2 expression on the cell surface and contains high levels of $G\alpha15$ to couple the receptor to the calcium signaling pathway.

^{§:} GenScript employs a PCR-based method to test the mycoplasma. The test covers 11 of the most common strains of mycoplasma, (covering approximately 95% of M. fermentans, M. hyorhinis, M. arginini, M. orale, M. salivarium, M. hominis, M. arthritidis, M. neurolyticum, M. hyopneumoniae and M. capricolum) and one species Ureaplasma (U. urealyticum), with sufficient sensitivity and specificity.



III. REPRESENTATIVE DATA

Concentration-dependent stimulation of intracellular calcium mobilization by Oxotremorine in CHO-K1/Gα15/M2 and CHO-K1/Gα15 cells




Figure 1. Oxotremorine-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/G α 15/M2 and CHO-K1/G α 15 cells. The cells were loaded with Calcium-4 prior to stimulation with an M2 receptor agonist, Oxotremorine. The intracellular calcium change was measured by FlexStation. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (10-fold dilution) of Oxotremorine (Mean \pm SD, n = 2). The EC₅₀ of Oxotremorine on M2 in CHO-K1 cells was 6.4 nM. The S/B of Oxotremorine on M2 in CHO-K1 cells was 10.

Notes:

1. EC₅₀ value is calculated with four parameter logistic equation:

Y=Bottom + (Top-Bottom)/(1+10^((LogEC₅₀-X)*HillSlope))

X is the logarithm of concentration.

Y is RFU and starts at Bottom and goes to Top with a sigmoid shape.

2. Signal to background Ratio (S/B) = Top/Bottom



IV. RADIOLIGAND BINDING ASSAY




Figure 2. 10 μg of membranes prepared from CHO-K1 cells stably expressing M2 receptors were incubated with indicated concentrations of [³H]N-Methylscopolamine ([³H]NMS) in the absence (total binding) or presence of 1000- fold access unlabeled Atropine (nonspecific binding, NSB). Binding was terminated by rapid filtration. Specific binding was defined by subtracting NSB from total binding. Data were fit to one-site binding equation using a non-linear regression method.

100-80-100-80-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-10

Competition Binding for M2 Receptor

Figure 3. 10 μg of membranes prepared from CHO-K1 cells stably expressing M2 receptors were incubated with indicated concentrations of Atropine in the presence of 0.2 nM [³H]N-Methylscopolamine ([³H]NMS). Binding was terminated by rapid filtration. Data were fit to one-site competition equation using a non-linear regression method.

Log[Atropine] M



V. THAWING AND SUBCULTURING

Thawing Protocol

- 1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
- 2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
- 3. Pellet cells by centrifugation at 200 x g force for 5 min, and remove the medium.
- 4. Resuspend the cells in complete growth medium.
- 5. Transfer the cell suspension to a 10 cm dish with 10 ml of complete growth medium.
- 6. Grow the cells in incubator with 37°C, 5 %CO₂.
- 7. In the following day, replace the cells with fresh medium contains antibiotic.

Sub-culturing Protocol

- Remove the culture medium from cells.
- 2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
- 3. Add 2.0 ml of 0.05% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25300) solution into 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).
 - Note: To avoid cells clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells detach. If cells are difficult to detach, please place the dish in 37°C incubator for ~2 min.
- 4. Add 6.0 to 8.0 ml of complete growth medium into dish and aspirate cells by gently pipetting.
- 5. Centrifuge the cells at 200 x g force for 5min, and remove the medium.
- 6. Resuspend the cells in culture medium and add the cells suspension to new culture dish.
- 7. Grow the cells in incubator with 37°C, 5 %CO₂.

Subcultivation Ratio: 1:3 to 1:8 weekly. Medium Renewal: Every 2 to 3 days

VI. REFERENCES

- 1. Goin JC, Nathanson NM. (2006) Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells: regulation of receptor down-regulation by heterodimerization. *J Biol Chem.*, 281(9):5416-25
- 2. Cembala TM *et al.* (1998) Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. *Br. J. Pharmacol.* 125(5):1088-94.
- 3. Mary H *et al.* (1995) Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists. *Br J Pharmacol.* 114(6):1241-9.
- 4. Schwarz RD *et al.* (1993) Characterization of muscarinic agonists in recombinant cell lines. *Life Sci.* 52(5-6):465-72.



GenScript USA Inc,

860 Centennial Ave. Piscataway, NJ 08854

Toll-Free: 1-877-436-7274

Tel: 1-732-885-9188, Fax: 1-732-210-0262

Email: product@genscript.com
Web: http://www.genscript.com

For Research Use Only.

Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- The products are not transferable and will be used at the site where they were purchased. Transfer to another site
 owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by
 GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products sold by GenScript are for laboratory and animal research purposes only. The products are not to be used on humans, for consumption, or for any unlawful uses.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for other purposes, contact Marketing Department, GenScript USA Inc., 120 Centennial Avenue, Piscataway, New Jersey 08840, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: marketing@genscript.com.